Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on BridgeBio Pharma and increased the price target to $80.00 from $70.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ram Selvaraju has given his Buy rating due to a combination of factors, primarily the impressive results from BridgeBio Pharma’s Phase 3 FORTIFY trial for their lead candidate BBP-418. The trial demonstrated significant improvements in key biomarkers and clinical endpoints for patients with limb girdle muscular dystrophy type 2I/R9, with statistically significant increases in glycosylated alpha-dystroglycan and reductions in serum creatine kinase. These results suggest a strong correlation between biomarker impact and functional benefits, supporting a favorable risk-benefit profile for BBP-418.
Furthermore, the potential for BBP-418’s market entry in late 2026, coupled with its previous designations as an Orphan Drug and Fast Track status, enhances its approval prospects. BridgeBio’s plans to engage with the FDA and submit a New Drug Application in the first half of 2026 further solidify the outlook. The anticipated pricing strategy, in line with other high-cost muscular dystrophy treatments, also contributes to the positive valuation assessment, leading to an increased price target of $80 per share.
In another report released yesterday, Raymond James also maintained a Buy rating on the stock with a $69.00 price target.